* UNITY Biotechnology Inc UBX.OQ reported a quarterly
adjusted
loss of 76 cents per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of $1.08 per share.
* Reported revenue was zero; analysts expected zero.
* UNITY Biotechnology Inc's reported EPS for the quarter was
a
loss of 76 cents.
* The mean earnings estimate of analysts had risen by
about 2.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* UNITY Biotechnology Inc shares had risen by 46.9% this
quarter and lost 12.6% so far this year.
* The company reported a quarterly loss of $10.87 million.
* Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $10.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data May
9 at 11:59 p.m. UTC. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2023 -1.08 -0.76 Beat
Dec. 31 2022 -1.05 -1.00 Beat
Sep. 30 2022 -1.65 -1.36 Beat
Jun. 30 2022 -2.80 -1.90 Beat